Evaluation of Pentraxin-3 levels in children with multisystem inflammatory syndrome
Open Access
- 2 December 2024
- journal article
- research article
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 35 (2) , 317-323
Abstract
Background: Early recognition of cardiac involvement and prediction of disease prognosis are essential for the management of inflammatory diseases such as multisystem inflammatory syndrome. This study aimed to investigate the role of Pentraxin-3 levels in identifying cardiac involvement and evaluating disease severity in patients with multisystem inflammatory syndrome.Methods: The study included 56 multisystem inflammatory syndrome patients and 26 healthy children as a control group. The multisystem inflammatory syndrome group was divided into those with cardiac involvement (n = 34) and those without (n = 22), as well as those with clinically mild-moderate (n = 30) and severe (n = 26) multisystem inflammatory syndrome. Blood samples for measurement of Pentraxin-3 levels were obtained from all patients before treatment and from the healthy controls.Results: In the patient group, the mean age was 8.2 ± 4 years (range: 2–17 years), and the male-to-female ratio was 1.8. In the control group, these values were 9.5 ± 3.7 years (range: 2–16 years) and 1.9, respectively (p > 0.05). Plasma Pentraxin-3 levels were significantly higher in multisystem inflammatory syndrome patients compared to controls (7.1 ± 5 ng/mL vs. 2.9 ± 2.1 ng/mL, p = 0.001). Patients with cardiac involvement had a significantly higher median Pentraxin-3 level than those without (5.8 ng/mL vs. 4.1 ng/mL, p = 0.004). Severe disease was also associated with a higher median Pentraxin-3 level compared to mild-moderate disease (6.1 ng/mL vs. 4.4 ng/mL, p = 0.001). Pentraxin-3 level was negatively correlated with left ventricular ejection fraction and positively correlated with B-type natriuretic peptide, troponin.Conclusion: Elevated Pentraxin-3 levels in multisystem inflammatory syndrome patients may help predict the clinical course of the disease and cardiac involvement. However, larger-scale prospective studies are needed to further elucidate this.Keywords
This publication has 28 references indexed in Scilit:
- Longitudinal Cardiac Outcomes of Multisystem Inflammatory Syndrome in Children: A Systematic Review and Meta-AnalysisPediatric Cardiology, 2022
- Advances in understanding Kawasaki disease‐related immuno‐inflammatory response and vascular endothelial dysfunctionPediatric Investigation, 2022
- Multisystem inflammatory syndrome (MIS-C): a systematic review and meta-analysis of clinical characteristics, treatment, and outcomesJornal de Pediatria, 2021
- The immune landscape of SARS-CoV-2-associated Multisystem Inflammatory Syndrome in Children (MIS-C) from acute disease to recoveryiScience, 2021
- Pentraxin-3 and endothelial dysfunction2019
- Pentraxin-3 as a marker of sepsis severity and predictor of mortality outcomes: A systematic review and meta-analysisJournal of Infection, 2018
- Pentraxin 3 Is a New Inflammatory Marker Correlated With Left Ventricular Diastolic Dysfunction and Heart Failure With Normal Ejection FractionJACC, 2011
- PTX3 expression in the heart tissues of patients with myocardial infarction and infectious myocarditisCardiovascular Pathology, 2011
- Increase in tissue and circulating pentraxin3 levels in patients with aortic valve stenosisAmerican Heart Journal, 2010
- Pentraxins in Innate Immunity: From C-Reactive Protein to the Long Pentraxin PTX3Journal of Clinical Immunology, 2007